GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IVERIC bio Inc (NAS:ISEE) » Definitions » Cyclically Adjusted Price-to-FCF

IVERIC bio (IVERIC bio) Cyclically Adjusted Price-to-FCF : (As of May. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is IVERIC bio Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


IVERIC bio Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for IVERIC bio's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVERIC bio Cyclically Adjusted Price-to-FCF Chart

IVERIC bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IVERIC bio Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IVERIC bio's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, IVERIC bio's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IVERIC bio's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IVERIC bio's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where IVERIC bio's Cyclically Adjusted Price-to-FCF falls into.



IVERIC bio Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

IVERIC bio's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, IVERIC bio's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.371/127.3478*127.3478
=-0.371

Current CPI (Mar. 2023) = 127.3478.

IVERIC bio Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201306 -0.229 98.518 -0.296
201309 -7.110 98.790 -9.165
201312 -0.814 98.326 -1.054
201403 -0.523 99.695 -0.668
201406 4.824 100.560 6.109
201409 -1.295 100.428 -1.642
201412 0.309 99.070 0.397
201503 -0.896 99.621 -1.145
201506 0.442 100.684 0.559
201509 -0.709 100.392 -0.899
201512 -1.144 99.792 -1.460
201603 -1.044 100.470 -1.323
201606 -0.941 101.688 -1.178
201609 -0.166 101.861 -0.208
201612 -0.928 101.863 -1.160
201703 -1.718 102.862 -2.127
201706 -0.864 103.349 -1.065
201709 -0.446 104.136 -0.545
201712 -0.367 104.011 -0.449
201803 -0.334 105.290 -0.404
201806 -0.246 106.317 -0.295
201809 -0.299 106.507 -0.358
201812 -0.253 105.998 -0.304
201903 -0.352 107.251 -0.418
201906 -0.235 108.070 -0.277
201909 -0.294 108.329 -0.346
201912 -0.268 108.420 -0.315
202003 -0.328 108.902 -0.384
202006 -0.222 108.767 -0.260
202009 -0.159 109.815 -0.184
202012 -0.227 109.897 -0.263
202103 -0.316 111.754 -0.360
202106 -0.219 114.631 -0.243
202109 -0.249 115.734 -0.274
202112 -0.194 117.630 -0.210
202203 -0.317 121.301 -0.333
202206 -0.301 125.017 -0.307
202209 -0.344 125.227 -0.350
202212 -0.395 125.222 -0.402
202303 -0.371 127.348 -0.371

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IVERIC bio  (NAS:ISEE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


IVERIC bio Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of IVERIC bio's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


IVERIC bio (IVERIC bio) Business Description

Industry
Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, New Jersey, USA, 07054
IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.
Executives
Keith Westby officer: SVP & COO ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
David Francis Carroll officer: SVP, CFO and Treasurer ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Glenn Sblendorio director 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Christopher Paul Simms officer: Senior Vice President, CCO FIVE PENN PLAZA SUITE 2372, NEW YORK NY 10001
Anthony S Gibney officer: EVP, Chief Business Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Calvin W. Roberts director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Christine Ann Miller director 5 PENN PLAZA, SUITE 2372, NEW YORK NY 10001
Pravin Dugel officer: EVP, Chief Strategy & Business C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
David R Guyer director, officer: Chief Executive Officer ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
Mark S. Blumenkranz director C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Versant Venture Capital Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Jane Henderson director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142